The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus

Pediatrics

Volumn 124, Issue 6, 2009, Pages 1676-1679

  Meissner, H Cody ^a   Bocchini Jr , Joseph A ^b   Brady, Michael T ^c   Hall, Caroline B ^d   Kimberlin, David W ^e   Pickering, Larry K ^f  

^a TUFTS MEDICAL CENTER   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERIMMUNE GLOBULIN; MONOCLONAL ANTIBODY; PALIVIZUMAB; PLACEBO;

ANTIBODY BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE PREDISPOSITION; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INNATE IMMUNITY; NOTE; PASSIVE IMMUNIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK FACTORS; UNITED STATES;

EID: 71949111112     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-2346     Document Type: Note

References (27)

1. Henderson FW, Collier AM, Clyde WAS, Denny FW. Respiratory syncytial virus infections, reinfection and immunity: a prospective longitudinal study in young children. N Engl J Med. 1979;300(10):530-534
2. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009; 360(6):588-598
3. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of RSV immune globulin to high-risk infants and young children. N Engl J Med. 1993;329(21): 1524-1530
4. PREVENT Study Group. Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93-99
5. Simoes EAF, Sondheimer HM, Top FH Jr, et al. Respiratory syncytial virus immune globulin for prophylaxis against RSV disease in infants and children with congenital heart disease. J Pediatr. 1996;133(4):492-499
6. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3): 531-537 (Pubitemid 28409250)
7. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-540
8. American Academy of Pediatrics, Committee on Infectious Diseases. Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-1701
9. Kamal-Bahl S, Doshi J, Campbell J. Economic analysis of RSV immunoprophylaxis in high-risk infants. Arch Pediatr Adolesc Med. 2002;156(10):1034-1041
10. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. RSV and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2006;154(1):55-61
11. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics. 2004;114(6):1606-1611 (Pubitemid 41754926)
12. Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence form the North Carolina Medicaid Program. Pediatrics. 2004;114(6): 1612-1619 (Pubitemid 41754927)
13. Elhassan NO, Sorbero MES, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006;160(10):1070-1076
14. Wang D, Cummins C, Bayliss S, Sardercock J, Burls A. Immunoprophylaxis against RSV with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008;12(36):iii, ix-x, 1-86
15. IMpact-RSV study group report. Pediatrics. 1999;104(4 pt 1):993-995
16. Singleton RJ, Bruden D, Bulkow LR. RSV season and hospitalizations in the Alaskan Yukon-Kuskokwim delta. Pediatr Infect Dis J. 2007;26(11 suppl):S46-S50
17. Wang EEL, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126(2):212-219
18. Carbonell-Estrany X, Quero J. Hospitalization rates for RSV infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001;20(9): 874-879 (Pubitemid 32880323)
19. Bulkow LR, Singleton RJ, Karron RA, Harrison LH; Alaska RSV Study Group. Risk factors for severe RSV infection among Alaska native children. Pediatrics. 2002;109(2): 210-216
20. Simoes EAF. Environmental and demographic risk factors for RSV lower respiratory tract disease. J Pediatr. 2003;143(5 suppl):S118-S126
21. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23(9):806-814 (Pubitemid 40221021)
22. Figueras-Aloy, Carbonell-Estrany X, Quero J. Case-control study of the risk factors linked to RSV infection requiring hospitalization in premature infants born at a gestation age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23(9):815-820 (Pubitemid 40221022)
23. Figueras-Aloy J, Carbonell-Estrany X, Quero- Jimenez J, et al. Flip-2 study: risk factors linked to RSV infection requiring hospitalization in premature infants born in Spain at a gestational age of 32-35 weeks. Pediatr Infect Dis J. 2008;27(9):788-793
24. Synagis [package insert]. Gaithersburg, MD: MedImmune; 2009
25. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep. 2008;57(17): 462-465
26. Centers for Disease Control and Prevention. ACIP provisional recommendations for the prevention of human rabies. Available at: www.cdc.gov/vaccines/recs/provisional/ downloads/rabies-July2009-508.pdf. Accessed August 21, 2009
27. Abarca K, Jung E, Fernandez P, et al. Safety, tolerability, pharmacokinetics and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of RSV infection in at-risk children. Pediatr Infect Dis J. 2009;28(4): 267-272